Methods and compositions for treating cancer

• US 10,702,540 B2
• Filed: 09/13/2017
• Issued: 07/07/2020
• Est. Priority Date: 08/25/2006
• Status: Active Grant

• Current Assignee: JANSSEN ONCOLOGY, INC. (Johnson & Johnson)
• Original Assignee: JANSSEN ONCOLOGY, INC. (Johnson & Johnson)
• Inventors: Auerbach, Alan H., Belldegrun, Arie S., de Bono, Johann
• Primary Examiner(s): Hui, San Ming R
• Application Number:
  US15/703,773
• Publication Number:
  US 20180000840A1
• Time in Patent Office: 1,028 Days
• Field of Search: 514170, 514182
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17α-hydroxylase/C_{17, 20}-lyase inhibitor, such as abiraterone acetate (i.e., 3β-acetoxy-17-(3-pyridyl) androsta-5, 16-diene), in combination with at least one additional therapeutic agent such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising a 17α-hydroxylase/C_{17, 20}-lyase inhibitor, and at least one additional therapeutic agent, such as an anti-cancer agent or a steroid.

Claims

1. A method for the treatment of a refractory prostate cancer in a human comprising administering to said human a therapeutically effective amount of at least two anti-cancer agents, wherein the at least two anti-cancer agents are:

(a) abiraterone acetate or a pharmaceutically acceptable salt thereof, and

(b) a prednisolone.

2. The method of claim 1, wherein the therapeutically effective amount of the abiraterone acetate or pharmaceutically acceptable salt thereof is from about 500 mg/day to about 1500 mg/day.

3. The method of claim 2, wherein the therapeutically effective amount of the prednisolone is from about 0.25 mg/day to about 50 mg/day.

4. The method of claim 2, wherein the therapeutically effective amount of the prednisolone is from about 5 mg/day to about 10 mg/day.

5. The method of claim 4, wherein the therapeutically effective amount of the prednisolone is about 10 mg/day.

6. The method of claim 1, wherein the prednisolone is selected from prednisolone acetate, prednisolone sodium phosphate, and prednisolone tebutate.

7. The method of claim 1, wherein the refractory prostate cancer is metastatic refractory prostate cancer.

8. The method of claim 1, wherein the amount of the prednisolone is effective to enhance the response of the refractory prostate cancer to abiraterone acetate or a pharmaceutically acceptable salt thereof.

9. The method of claim 1, wherein the amount of the prednisolone is effective to reduce the resistance of the refractory prostate cancer to abiraterone acetate or a pharmaceutically acceptable salt thereof.